pharmaphorum

pharmaphorum Podcast

Science EN ↓ 368 episodes

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.

Be sure to visit the podcast's website and support the creator: pharmaphorum.podbean.com

Author

pharmaphorum

Category

Science

Podcast website

pharmaphorum.podbean.com

Latest episode

Nov 20, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

EAPs: Market access outside of the US and Western Europe 19.05.2025

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean. Market access strategies in many international mark...

The value of a partner, globally and locally 09.05.2025

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead. Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP &...

The ins and outs of HEOR – A lever for global health 06.05.2025

ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary of the organisation. Ahead of the event, web editor Nicole Raleigh spoke with Rob Abbott, CEO and executive director of ISPOR – the leading professional society for HEOR globally – about the ins and outs and trends of HEOR. ISPOR’s mission is to adva...

Unpacking Trumps executive order on drug pricing with Alice Valder Curran 02.05.2025

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders. But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomes Hogan Lovell...

AI in drug development: The real hurdle is implementation 01.05.2025

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn. AI, about how the real hurdle in clinical research lies in effectively integra...

Patients as active consumers of care: AI-driven personalisation in pharma marketing 29.04.2025

Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it. In a new pharmaphorum podcast, web editor Nicole...

Driving the drug discovery pipeline: The value of organ-on-a-chip MPS 22.04.2025

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease stat...

Intelligent regulatory compliance and improved patient outcomes 16.04.2025

Across the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outc...

Prevention for a healthier, more productive society 15.04.2025

In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare. Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring th...

Safeguarding the pharmaceutical supply chain 02.04.2025

As we hear of the volcanic and seismic activity taking place in Iceland this week, pharmaphorum turns back to a conversation with Dean Alms, CPO of Aravo, on how extreme weather highlights the need to make adequate supply chain preparations for the seasons in which the planet pulls out all the stops with the worst of its natural disasters. Having a blueprint for supply chain resiliency is critical...

For the continuum of mental health we need a whole system, holistic 'healthspan' 31.03.2025

If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow. What can be done to address the issue, though? At Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh sat down with Dr Sebastian Vaughn, CEO of Phytome Life Sciences, for an en plein air and explorative conversation around the topic, live onsite at The Ede...

IRA updates and making sense of the chaos in Washington, with Alice Valder Curran 20.03.2025

Last year, Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert in Washington, D.C. joined host Jonah Comstock on the pharmaphorum podcast to talk about the intended and unintended consequences of the drug pricing negotiation provisions in the Inflation Reduction Act. On today’s episode, Curran joins us once again for an update on the IRA, looking at the second batch of d...

GenAI and the revolution of drug development 05.03.2025

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life sciences sector can speed up the process, wiping months or even years off that average. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionisi...

Patient-focused manufacturing models for personalised therapies 28.02.2025

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs in...

On specialty pharmacies and prior authorisations 26.02.2025

Prior authorisations (or PAs) have long put a burden on pharmacy and medical practices, ultimately causing delays for patients.  In a new podcast, web editor Nicole Raleigh speaks with Andrew Burns, chief revenue officer at DrFirst, about the ramifications of delayed patient care when it comes to specialty medications. Exploring the current PA landscape, the conversation touches upon specialty pha...

Paediatric rare diseases: Children are not small adults 20.02.2025

Around 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients dying before the age of five, the need for different treatment methods for children is clear. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Children’s Nati...

Defining, building, and implementing in the next wave of biopharma R&D 13.02.2025

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma breakthroughs. PharmaLex’s Dr Christian Schneider, VP & Chief Medical Officer, Clinical Development Services, together with Dr Christelle Boileau, Director of Regulatory Development Strategy and IPD solution lead at PharmaLe...

Insights from JP Morgan Healthcare 2025: Key trends shaping the pharma industry 06.02.2025

The JP Morgan Healthcare Conference remains one of the most influential events for the life sciences sector, setting the stage for major deal-making, investment trends, and strategic shifts that will define the year ahead. Keen to capture all the key trends and talking points from this year’s event, pharmaphorum editor-in-chief, Jonah Comstock, hit the ground running in Philadelphia,  live bloggin...

‘Show me the molecule’ – On synthetic biology and cutting through AI hype 04.02.2025

Therapeutic antibodies are a vital weapon in combating diseases such as cancer, but developing these treatments through conventional methods is slow and unreliable. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug discovery company pioneering the discovery of next-generation therapeutic antibodies in order to solve this predic...

Simulated clinical trial populations and AI scalability 30.01.2025

AI might still be in the modish buzzword stage, but discussions exploring the potential for its scaling within life sciences are critical. In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores the potential for scaling advanced technologies in the biopharm...

Rare disease and the women's health gap 23.01.2025

For women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every on...

From science fiction to reality: AI in drug development 15.01.2025

With about 92% of new drugs failing in human clinical trials, pharma companies face tremendous financial losses and, more importantly, development and delivery of potentially life-saving treatments are woefully delayed. In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris. AI, about how AI could revolutionise preclinical research and ac...

Precision medicine, NGS, and the quantum leap in biomarkers 18.12.2024

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers. Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent compan...

Seeking effective, safe treatment for all with precision dosing 11.12.2024

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options. Creating new medicines by enhancing protein function, Richon is driven by the...

Seeking effective, safe treatment for all with precision dosing 03.12.2024

Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that recognises biological individuality – especially when it comes to paediatric care. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Sharmeen Roy, chief scientist at DoseMe, for a conversation on precision medicine tools and how pharmacokinetic (or PK) and pha...

Listen to the pharmaphorum Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.